The increasing prevalence of reproductive health disorders and growing demand for male and female infertility treatments are supporting market growth in the US. Healthcare providers are using HCG-based therapies in selected fertility treatment protocols to stimulate ovulation and support reproductive hormone functions. Increasing access to specialized fertility services is further contributing to market development.

Market Overview

The Human Chorionic Gonadotropin (hCG) Market was valued at US$1.21 billion in 2024 and is expected to reach US$1.85 billion by 2031, registering a CAGR of 6.2% during 2025–2031, according to The Insight Partners. The market is segmented by technology into natural source extraction and recombinant technology; by therapeutic area into female infertility treatment, male hypogonadism, and oligospermic treatment; and by end user into fertility clinics and research institutions. The report also projects a total addressable market of about US$10.85 billion across 2025–2031.

hCG is a hormone used in several therapeutic settings, most prominently in fertility care. It is produced through natural source extraction or recombinant technology, and demand comes from clinics, researchers, and patients. Better reproductive health awareness and continued product innovation are supporting the market.

Download Sample PDF: https://www.theinsightpartners.com/sample/TIPRE00004577

Boosting Fertility Treatments with hCG Innovations

Fertility treatment is the central driver of this market. hCG is used in infertility care for both women and men, and ongoing innovation is improving how products are developed and delivered. Recombinant technology in particular offers manufacturers a route to consistent, well-characterized products.

As more couples seek fertility support, demand for reliable hormone therapies may continue to grow. Fertility clinics are a core end-user group, and research institutions also contribute demand.

Growing Awareness in Reproductive Health

Greater awareness of reproductive health is encouraging people to seek diagnosis and treatment earlier. Conditions such as male hypogonadism and oligospermia are receiving more attention, which widens the patient pool for hCG-based therapies.

Educational efforts and improved access to specialist care may further support demand across regions.

Consumer Interest in Weight Loss Programs

The report notes that use of hCG in weight loss programs is a growth driver. Regulators take a cautious view here. In the US, the FDA has stated that hCG is not approved for weight loss, and the drug’s approved uses are in areas such as fertility. Companies in this space should be careful about claims and compliance, and consumers should follow the advice of a qualified healthcare professional.

Key Trends Shaping the Market

• Personalized treatments: Treatment plans tailored to individual patient needs, particularly in fertility care, are a rising trend.

• Innovative delivery systems: Improvements in how hCG is administered aim to make treatment more convenient and improve the patient experience.

• Growing interest in natural hCG products: Awareness is boosting demand for natural-source products, which supports the natural source extraction segment.

Market Opportunities

The report highlights three opportunity areas:

• Fertility solutions for couples: Innovative hCG products for couples who need support remain the clearest opportunity, backed by rising awareness and clinic capacity.

• Weight loss interest: The report points to growing consumer interest. Any commercial activity here is subject to strict regulatory scrutiny and should stay within approved uses and claims.

• Sports medicine: The report also cites sports medicine as a possible area. This is also tightly regulated, and anti-doping rules restrict hCG use in competitive sport.

Top Players in the Human Chorionic Gonadotropin (hCG) Market

The Insight Partners profiles the following companies in its report:

• Merck & Co, Inc

• Ferring B.V.

• Fresenius Kabi AG

• Cigna

• Sun Pharmaceutical Industries Ltd

• Lee BioSolutions Inc

• Sanzyme

• Scrippslabs

• Lupin AB

• Prospec-Tany Technogene Ltd

Participants compete through product quality, innovation, regulatory compliance, and distribution reach. The list is not presented as a ranking.

Market Segmentation

By Technology

• Natural Source Extraction

• Recombinant Technology

By Therapeutic Area

• Female Infertility Treatment

• Male Hypogonadism

• Oligospermic Treatment

By End User

• Fertility Clinics

• Research Institutions

By Geography

• North America

• Europe

• Asia Pacific

• South and Central America

• Middle East and Africa

Regional Outlook

The United States is identified as a key market, supported by fertility treatment innovation, wider use of hCG, and rising reproductive health awareness. The report’s North America analysis covers the US, Canada, and Mexico.

Europe covers the UK, Germany, France, Russia, Italy, and the rest of Europe. Asia Pacific covers China, India, Japan, Australia, and the rest of the region. South and Central America covers Brazil, Argentina, and other countries, and the Middle East and Africa covers South Africa, Saudi Arabia, the UAE, and other countries.

Future Outlook

The market is projected to grow from US$1.21 billion in 2024 to US$1.85 billion by 2031, according to The Insight Partners. Growth is expected to be supported by fertility treatment innovation, reproductive health awareness, personalized therapies, and new delivery systems.

At the same time, regulatory requirements, quality standards, and competition will continue to shape the market. Companies that focus on approved therapeutic uses and reliable manufacturing are likely to be best placed for the growth ahead.

Related Reports –

Infertility Testing Market Size, Share & Industry Growth by 2031

About Us

The Insight Partners, we provide comprehensive analysis and insights into market trends that empower businesses to make informed decisions. Our reports are designed to equip stakeholders with the necessary information to navigate the complexities of various industries, including healthcare, technology, and finance. We are dedicated to delivering high-quality research that enables our clients to achieve their strategic objectives.

Contact Us:
Contact Person: Ankit Mathur
E-mail: [email protected]
Phone: +1-646-491-9876

Also Available in : Korean German Japanese French Chinese Italian Spanish